BNP serves as a valuable noninvasive biomarker for risk stratification and guiding therapy in PAH, with potential future applications as a therapeutic agent.
No takes yet. Share an insight, caveat, or question.
BNP supports noninvasive risk stratification in PAH; leaves open whether levels should guide therapy or serve as a target.
James Klinger (2009) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: